Sickle Cell Disease Clinical Trials in Columbus, Ohio

6 studies are recruiting for sickle cell disease in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Ohio State Univ Wexner Med Ctr, Columbus, Ohio

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

2. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Ohio State University Medical Center, Columbus, Ohio

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

3. Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

   This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigili…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University, Columbus, Ohio

   Locations

   16 in total

   Run by

   CSL Behring

   See if you can join NCT07224360 on ClinicalTrials.gov

4. Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

   This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynam…

   Stage

   Phase 1

   Ages

   12 to 50

   Site

   Nationwide Children's Hospital, Columbus, Ohio

   Locations

   6 in total

   Run by

   Kamau Therapeutics

   See if you can join NCT04819841 on ClinicalTrials.gov

5. Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease

   In a hybrid type I effectiveness-implementation trial, our three-center research teams aim to examine whether empowering adults with sickle cell disease (SCD) with patient-facing SCD-specific guidelines through an mHealth application with booklets will decrease acute healthcare utilization and be c…

   Stage

   Not phased

   Ages

   18 and older

   Site

   The Ohio State University Medical Center, Columbus, Ohio

   Locations

   4 in total

   Run by

   Ohio State University

   See if you can join NCT06919224 on ClinicalTrials.gov

6. Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

   This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate …

   Stage

   Phase 2

   Ages

   2 to 25

   Site

   Nationwide Children's Hospital, Columbus, Ohio

   Locations

   7 in total

   Run by

   Robert Nickel

   See if you can join NCT03587272 on ClinicalTrials.gov